6月9日 - ** 药物开发商Metsera MTSR.O股价盘前上涨17.28%至32.24美元
** 该公司称 (link)，其试验性减肥药MET-233i在36天的小型早期试验中，经安慰剂调整后体重减轻了8.4%。
** MET-233i是一种长效注射月淀粉样蛋白类似物，目前正被开发为一种独立的治疗药物，也可与另一种试验性GLP-1药物MET-097i联合使用。
** 该试验在 80 名患有超重或肥胖症但未患 2 型糖尿病的参与者中研究了 MET-233i
** 自 1 月份上市以来，截至上次收盘，股价上涨了 3.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.